HemaSphere (Jun 2022)
P1160: RESULTS OF A PHASE 2 EXPANDED ACCESS STUDY OF ZANUBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA
- J. J. Castillo,
- E. C. Kingsley,
- M. Narang,
- H. A. Yimer,
- C. A. Dasanu,
- J. M. Melear,
- M. Coleman,
- C. M. Farber,
- M. Gupta,
- J. Shulman,
- E. H. Mantovani,
- X. Zhang,
- A. Cohen,
- J. Huang
Affiliations
- J. J. Castillo
- 1 Dana-Farber Cancer Institute, Boston, MA
- E. C. Kingsley
- 2 Comprehensive Cancer Centers of Nevada, Las Vegas, NV
- M. Narang
- 3 US Oncology Research, Maryland Hematology Oncology, Columbia, MD
- H. A. Yimer
- 4 Texas Oncology, US Oncology Research, Tyler, TX
- C. A. Dasanu
- 5 Lucy Curci Cancer Center, Eisenhower Health, Rancho Mirage, CA
- J. M. Melear
- 6 US Oncology Research, Texas Oncology, Austin Midtown, Austin, TX
- M. Coleman
- 7 Clinical Research Alliance, New York, NY
- C. M. Farber
- 8 Atlantic Hematology Oncology, Morristown Medical Center, Morristown, NJ
- M. Gupta
- 9 Ridley-Tree Cancer Center at Sansum Clinic, Santa Barbara, CA
- J. Shulman
- 10 Icahn School of Medicine at Mount Sinai, New York, NY
- E. H. Mantovani
- 11 BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA, United States of America
- X. Zhang
- 11 BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA, United States of America
- A. Cohen
- 11 BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA, United States of America
- J. Huang
- 11 BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA, United States of America
- DOI
- https://doi.org/10.1097/01.HS9.0000847508.16968.e7
- Journal volume & issue
-
Vol. 6
pp. 1047 – 1048
Abstract
No abstracts available.